Omar Ishrak
Omar Ishrak's purchase track record
How the stock did after each of Omar Ishrak's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/30/2023 | INTC | $2K | +9.7% | +30.1% | +14.2% |
| 2/22/2022 | INTC | $497K | -6.0% | -22.7% | -4.1% |
| 10/28/2021 | INTC | $960K | +0.6% | -1.1% | -6.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Intel Shares Drop 3% Amid AI Chip Rotation. Intel shares fell 3% along with AMD as investors rotate out of AI‑focused chip names. The drop comes amid a broader selloff in the sector after concerns about an AI bubble. Analysts are watching Intel’s upcoming earnings to see if it can meet expectations.
Transaction History
| AMGN | ▲ Buy | Grant | 85 | $0 | 8/7/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 665 | $0 | 5/19/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 106 | $0 | 5/5/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 219 | $0 | 11/7/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 121 | $0 | 8/8/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 809 | $0 | 5/23/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 129 | $0 | 5/6/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 221 | $0 | 11/4/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 109 | $0 | 8/9/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 719 | $0 | 5/31/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 117 | $0 | 5/7/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 241 | $0 | 11/3/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 125 | $0 | 8/8/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 939 | $0 | 5/19/2023 | View on chart |
| INTC | ▲ Buy | Option Exercise | 4,828 | — | 5/11/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 138 | $0 | 5/2/2023 | View on chart |
| INTC | ▲ Buy | Open Market | 86 | $2K | 1/30/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 222 | $0 | 11/8/2022 | View on chart |
| AMGN | ▲ Buy | Grant | 131 | $0 | 8/9/2022 | View on chart |
| AMGN | ▲ Buy | Grant | 855 | $0 | 5/17/2022 | View on chart |
| INTC | ▲ Buy | Option Exercise | 3,720 | — | 5/12/2022 | View on chart |
| AMGN | ▲ Buy | Grant | 141 | $0 | 5/2/2022 | View on chart |
| INTC | ▲ Buy | Open Market | 11,025 | $497K | 2/22/2022 | View on chart |
| INTC | ▲ Buy | Open Market | 20,000 | $960K | 10/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Amgen Outperforms Market Amid Dow Jones Rotation
Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.
Amgen Outperforms Market Amid Dow Jones Rotation. Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.